Novartis Clozaril suicide indication
This article was originally published in Pharmaceutical Approvals Monthly
Novartis' Clozaril (clozapine) clears FDA Dec. 18 for reduction of suicidal behavior in schizophrenic and schizoaffective patients. The Dec. 18 approval significantly broadens Clozaril's patient population; the atypical antipsychotic was previously indicated for second-line use in severely ill schizophrenics. The indication is based on the 980-patient International Suicide Prevention Trial (InterSePT), which found Clozaril reduced the risk of suicide attempts by 25% compared to Lilly's Zyprexa (olanzapine). Novartis gains 36 months of exclusivity for the suicide indication; several generic versions of clozapine are available, but market erosion has been limited by required monitoring for agranulocytosi
You may also be interested in...
Despite AI and digital analytics playing an increasing role in pharma, the industry lags others globally, a recent event heard. Meanwhile, top Indian players including Sun Pharma, Cipla and others shared what is driving their initiatives, ranging from a 'touchless factory' to virtual training and lessons learned along the way.
Hologic made its third big acquisition of 2021 and Agilent agreed to pay up to $695m for Resolution Bioscience to extend its precision oncology capabilities.
Broader than initially reported, Merck & Co.’s agreement with BARDA extends beyond J&J’s recently authorized vaccine to other COVID-19 vaccines and therapeutics as needed.